These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36806572)

  • 21. Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
    Lin Y; Ahmed W; He M; Xiang X; Tang R; Cui ZN
    Eur J Med Chem; 2020 Dec; 207():112795. PubMed ID: 33002845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.
    González-García C; Bravo B; Ballester A; Gómez-Pérez R; Eguiluz C; Redondo M; Martínez A; Gil C; Ballester S
    Br J Pharmacol; 2013 Oct; 170(3):602-13. PubMed ID: 23869659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
    Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
    Bioorg Med Chem; 2013 Nov; 21(22):7025-37. PubMed ID: 24094436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.
    Zhou ZZ; Cheng YF; Zou ZQ; Ge BC; Yu H; Huang C; Wang HT; Yang XM; Xu JP
    ACS Chem Neurosci; 2017 Jan; 8(1):135-146. PubMed ID: 27690383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
    Song G; Zhu X; Li J; Hu D; Zhao D; Liao Y; Lin J; Zhang LH; Cui ZN
    Bioorg Med Chem; 2017 Oct; 25(20):5709-5717. PubMed ID: 28888661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based optimization of Toddacoumalone as highly potent and selective PDE4 inhibitors with anti-inflammatory effects.
    Zhou F; Huang Y; Liu L; Song Z; Hou KQ; Yang Y; Luo HB; Huang YY; Xiong XF
    Biochem Pharmacol; 2022 Aug; 202():115123. PubMed ID: 35688178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PdCl
    Thirupataiah B; Mounika G; Reddy GS; Kumar JS; Hossain KA; Medishetti R; Samarpita S; Rasool M; Mudgal J; Mathew JE; Shenoy GG; Rao CM; Chatti K; Parsa KVL; Pal M
    Eur J Med Chem; 2021 Oct; 221():113514. PubMed ID: 33992926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.
    Ahluwalia J; Udkoff J; Waldman A; Borok J; Eichenfield LF
    Drugs; 2017 Sep; 77(13):1389-1397. PubMed ID: 28681318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.
    Guariento S; Bruno O; Fossa P; Cichero E
    Mol Divers; 2016 Feb; 20(1):77-92. PubMed ID: 26290462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel quinazolin-4(3H)-one/Schiff base hybrids as antiproliferative and phosphodiesterase 4 inhibitors: design, synthesis, and docking studies.
    Abdel-Rahman HM; Abdel-Aziz M; Canzoneri JC; Gary BD; Piazza GA
    Arch Pharm (Weinheim); 2014 Sep; 347(9):650-7. PubMed ID: 24985336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of 4-alkynyl pyrazoles as inhibitors of PDE4: a practical access via Pd/C-Cu catalysis.
    Gorja DR; Shiva Kumar K; Kandale A; Meda CL; Parsa KV; Mukkanti K; Pal M
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2480-7. PubMed ID: 22381049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of a novel class of PDE4 inhibitors with antioxidant properties as bifunctional agents for the potential treatment of COPD.
    Wang Y; Wang H; Yang G; Hao Q; Yang K; Shen H; Wang Y; Wang J
    Eur J Med Chem; 2023 Aug; 256():115374. PubMed ID: 37150057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors.
    Nunes IK; de Souza ET; Cardozo SV; Carvalho VF; Romeiro NC; Silva PM; Martins MA; Barreiro EJ; Lima LM
    PLoS One; 2016; 11(10):e0162895. PubMed ID: 27695125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
    Kato Y; Kawasaki M; Nigo T; Nakamura S; Fusano A; Teranishi Y; Ito MN; Sumiyoshi T
    Bioorg Med Chem; 2013 Sep; 21(18):5851-4. PubMed ID: 23910988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
    Tang L; Huang C; Zhong J; He J; Guo J; Liu M; Xu JP; Wang HT; Zhou ZZ
    Eur J Med Chem; 2019 Apr; 168():221-231. PubMed ID: 30822711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a PDE4-Specific Pocket for the Design of Selective Inhibitors.
    Feng X; Wang H; Ye M; Xu XT; Xu Y; Yang W; Zhang HT; Song G; Ke H
    Biochemistry; 2018 Jul; 57(30):4518-4525. PubMed ID: 29975048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
    Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphodiesterase-4 inhibition improves corticosteroid insensitivity in pulmonary endothelial cells under oxidative stress.
    Ortiz JL; Milara J; Lluch J; De Diego A; Sanz C; Cortijo J
    Allergy; 2013 Jan; 68(1):64-73. PubMed ID: 23121078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pd-mediated functionalization of polysubstituted pyrroles: their evaluation as potential inhibitors of PDE4.
    Bhaskar Kumar T; Sumanth Ch; Vaishaly S; Srinivasa Rao M; Chandra Sekhar KB; Meda CL; Kandale A; Rambabu D; Rama Krishna G; Malla Reddy C; Shiva Kumar K; Parsa KV; Pal M
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5639-47. PubMed ID: 22871579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
    Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
    Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.